Bristol Myers Squibb: Strong Pipeline, Weak Outlook (Rating Downgrade) [Seeking Alpha]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Seeking Alpha
BMY's growth portfolio now surpasses its legacy portfolio, yet overall revenue is expected to decline as analysts remain pessimistic about pipeline execution. Dividend yield stands at 4.3% and is well-covered by free cash flow, while debt levels, though reduced, require monitoring if revenue declines persist. Valuation is attractive on a free cash flow basis, but intrinsic value varies widely depending on growth assumptions, making BMY a hold rather than a clear buy. Frank Brennan/iStock Editorial via Getty Images About a year ago, I published my last article about the pharmaceutical company Bristol Myers Squibb Company ( BMY ), and I rated the stock as a “Buy” and also wrote that it is one
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol-Myers Squibb Company (BMY): Favorite for Conservative Portfolios [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug CompanyBusiness Wire
- Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration [Yahoo! Finance]Yahoo! Finance
- Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration [TheStreet.com]TheStreet.com
BMY
Earnings
- 2/6/26 - Beat
BMY
Sec Filings
- 4/17/26 - Form DEFA14A
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- BMY's page on the SEC website